Katherine Marx MS MPH FNPBC June 2014 Disclosure I Katherine Marx have no relevant financial professional or personal relationships to disclose Objectives Know current US recommendations for ID: 731611
Download Presentation The PPT/PDF document "PrEP : HIV Pre-exposure Prophylaxis" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
PrEP: HIV Pre-exposure Prophylaxis
Katherine Marx, MS, MPH, FNP-BC
June 2014Slide2
Disclosure
I, Katherine Marx, have no relevant financial, professional, or personal relationships to disclose.Slide3
Objectives
Know current US recommendations for PrEPIdentify candidates for PrEP
Learn about resources for providing
PrEPSlide4
Combination HIV Prevention
Biomedical InterventionsBehavioral InterventionsStructural InterventionsSlide5
Biomedical Interventions
PrEPPost-exposure prophylaxisTreatment as preventionDiagnosis and treatment of sexually transmitted infections
Prevention of mother-to-child
t
ransmission of HIV
Contraception to prevent unplanned pregnancy among women with HIV
Voluntary male
c
ircumcision
Blood safety
Injection safety
MicrobicidesSlide6
PrEP: Pre-exposure Prophylaxis
How does it work?Uninfected person takes antiretrovirals
May prevent replication of virus & infection
Daily adherence to TDF/FTC Slide7
NRTI
’
s and NNRTI
’
s work here
http://
www.aidsinfo.nih.gov
/education-materials/fact-sheets/19/73/the-
hiv
-life-cycleSlide8
June 2013
CDC Interim Guidance:
PrEP
for IDU
PrEP
Timeline
November 2010
iPrEx
January 2011
CDC Interim Guidance:
PrEP
for MSM
August 2012
TDF2
Partners
PrEP
August 2012
CDC Interim Guidance:
PrEP
for
heterosexuals
July 2012
FEM-
PrEP
June 2013
Bangkok TDF Study
July 2012
FDA Approval
TDF/FTC
PrEP
January 2014
NYS AIDS Institute
Guidance for
PrEP
May 2014US Public Health ServiceClinical Practice Guideline for PrEP
March 2013
VOICESlide9
PrEP Studies: HIV transmission risk lowest when participants took
PrEP consistently
STUDY
OVERALL
Reduction in risk of HIV infection
Detectable level of medication in the blood
Reduction in risk of HIV infection
iPrEx
44%
>90%
TDF2
62%
---
Partners
PrEP
75%
90%
BTS
49%
74%
Adapted from summary of research at http://www.cdc.gov/hiv/prevention/research/prep/Slide10Slide11Slide12
PrEP Utilization
Rawlings K, Mera R,
Pechonkina
A, et al. Status of
Truvada
for HIV pre-exposure prophylaxis (
PrEP
) in the United States: an early drug utilization analysis. 53rd ICAAC. September 10-13, 2013. Denver. Abstract H-663a.
Female
MaleSlide13
PrEP: Candidates
Substantial risk of acquiring HIV infectionMen who have sex with men (MSM)HIV-positive sexual partner
Recent bacterial STI
High number of sex partners
History of inconsistent/no condom use
Commercial sex work
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide14
PrEP: Candidates
Substantial risk of acquiring HIV infectionTransgender individualsEngaging in high-risk sexual behaviors
www.hivguidelines.orgSlide15
Risk Behavior Assessment for MSM
In the past 6 months:
Have you had sex with men, women, or both?
(if men or both sexes)
How many men have you had sex with?
How many times did you have receptive anal sex (you were the bottom) with a man who was not wearing a condom?
How many of your male sex partners were HIV-positive?
(if any positive)
With these HIV-positive male partners, how many times did you have
insertive
anal sex (you were the top) without you wearing the condom?
Have you used methamphetamines (such as crystal or speed)?
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide16
PrEP: Candidates
Substantial risk of acquiring HIV infectionHeterosexual women and menHIV-positive sexual partner
Recent bacterial STI
High number of sex partners
History of inconsistent/no condom use
Commercial sex work
High-prevalence area or network
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide17
PrEP: Candidates
Substantial risk of acquiring HIV infectionInjection drug users (IDU)HIV-positive injecting partner
Sharing injection equipment
Recent drug treatment (but currently injecting)
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide18
PrEP vs. nPEP
Case #1:24 year old white MSM who presents 4 hours after unprotected receptive anal sex, for the first time, with his HIV-infected partner.Slide19
nPEP
Non-occupational Post-exposure ProphylaxisHigh risk exposureAs soon as possible28 day course
Tenofovir
/
emtricitabine
+
raltegravir
www.hivguidelines.orgSlide20
PrEP vs. nPEP
Case #2:24 year old MSM on nPEP
, day 27/28. Struggles with consistent condom use and regularly has unprotected receptive anal intercourse with his HIV-infected partner.Slide21
PrEP: Clinical Eligibility
Documented negative HIV test No signs/symptoms of acute HIV infection
Normal renal function
No contraindicated medications
Documented hepatitis B infection & vaccination status
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide22
PrEP: HIV Testing
Are signs/symptoms of acute HIV present now or in prior 4 weeks?
Option 1: retest antibody in one month
Option 2: HIV antibody/antigen assay
Option 3: HIV-1 viral load
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide23
Acute HIV Infection
SymptomsFeverFatigueMyalgia
Skin rash
Headache
Pharyngitis
Cervical Lymphadenopathy
Arthralgia
Night sweats
Diarrhea
Daar
ES,
Pilcher
CD, Hecht
FM.
Curr
Opin HIV AIDS. 2008;3(1):10-15.Slide24
PrEP: Considerations
AgeReproductive planOsteopenia/osteoporosis
www.hivguidelines.orgSlide25
PrEP: Risk Reduction
Case #3:32 year old black female seeks pregnancy.
She is not infected with HIV.
Her partner is HIV-infected and not currently on antiretroviral treatment.Slide26
Providing PrEP
Before starting
PrEP
:
Clinical eligibility
Educate
Side effects
Limitations
Daily adherence
Symptoms of
seroconversion
Monitoring schedule
Safety
Criteria for discontinuation
Partner information
Social history: housing, substance use, mental health, domestic violence
Every visit:
Assess adherence
Risk reduction counseling
Provide condoms
www.hivguidelines.orgSlide27
Providing PrEP
After confirmation of clinical eligibility:Prescribe no more than 90-day supply of
PrEP
Truvada
1 tablet PO daily
(
tenofovir
300mg +
emtricitabine
200mg)
Insurance prior approval
Truvada
for
PrEP
Medication Assistance Program
Every visit:
Assess adherence
Risk reduction counseling
Provide condoms
http://
www.cdc.gov
/
hiv
/pdf/guidelines/PrEPguidelines2014.pdfSlide28
Providing PrEP
3-month visit:HIV testAssess for acute infection
Check for side effects
Pregnancy testing
Prescribe 90-day supply of medication
Every visit:
Assess adherence
Risk reduction counseling
Provide condoms
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide29
Providing PrEP
6-month
HIV test
STI test
Pregnancy test
Renal function
90 day prescription
9-month
HIV test
Pregnancy test
90 day prescription
12-month
HIV test
STI tests
Pregnancy test
Renal function
90 day prescription
Assess the need to continue
PrEP
Every visit:
Assess adherence
Risk reduction counseling
Provide condoms
http://
www.cdc.gov
/hiv/pdf/guidelines/PrEPguidelines2014.pdfSlide30
Support Adherence
Develop trust, avoid judgmentPlanMonitor
Educate
Identify barriers
Assess for side effects
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide31
Discontinuing PrEP
Positive HIV resultAcute HIV signs or symptomsNon-adherence
Renal disease
Changed life situation: lower HIV risk
http://
www.cdc.gov
/
hiv
/
pdf
/guidelines/PrEPguidelines2014.pdfSlide32
PrEP: Research
PrEP in the real worldIntermittent dosingNew medications
New formulationsSlide33
PrEP Summary
EffectiveFDA approvedWell-tolerated
However,
Short-term data only
Daily adherence required
Side effects
Drug resistance in acute infection
Could lead to fewer condoms being used
Cost
LogisticsSlide34
PrEP Resources
CDC: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf
NYSDOH AI:
http://www.hivguidelines.org/
PrEP
Watch/ AVAC:
http://www.prepwatch.org/Slide35
Additional Resources
NY/NJ AETC PrEP Webinarshttp://nynjaetc.virtualforum.com/pif.asp?Prog_ID=14060902&securitycode=KXbFYh
http://nynjaetc.virtualforum.com/pif.asp?Prog_ID=14052303&securitycode=01r27E
http://nynjaetc.virtualforum.com/pif.asp?Prog_ID=14050908&securitycode=o9k2C2Slide36
Katherine Marx, MS, MPH, FNP-BC